Dr Reddy's launches immuno-oncology drug Toripalimab in India for treating nasopharyngeal carcinoma

Dr. Reddy's Laboratories launched Zytorvi (Toripalimab), a novel immunotherapy drug for recurrent or metastatic nasopharyngeal carcinoma (NPC), a rare head and neck cancer. This marks India as the third country globally with access to this next-gen PD-1 inhibitor, offering a superior treatment alternative to standard chemotherapy. Dr.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8MyPe7D
via IFTTT